The metabolic switch and its regulation in cancer cells

Science China Life Sciences

Volumn 53, Issue 8, 2010, Pages 942-958

  Zhou, ShengTao ^a   Huang, CanHua ^a   Wei, YuQuan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

aerobic glycolysis; cancer; de novo fatty acid synthesis; glutaminolysis; metabolism

Indexed keywords

CELL CYCLE; HUMAN; METABOLISM; NEOPLASM; PATHOLOGY; REVIEW;

CELL CYCLE; HUMANS; NEOPLASMS;

EID: 77956486435     PISSN: 16747305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11427-010-4041-1     Document Type: Review

References (157)

1. Civitarese A E, Ravussin E. Minireview: Mitochondrial energetics and insulin resistance. Endocrinology, 2008, 149: 950-954.
2. Bobik A. Apolipoprotein CIII and atherosclerosis-Beyond effects on lipid metabolism Circulation, 2008, 118: 1467-1475.
3. Parkinson A, Mudra D R, Johnson C, et al. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol, 2004, 199: 193-209.
4. Hsu P P, Sabatini D M. Cancer cell metabolism: Warburg and beyond. Cell, 2008, 134: 703-707.
5. DeBerardinis R J, Lum J J, Hatzivassiliou G, et al. The biology of cancer: Metabolic reprogramming fuels cell growth and proliferation. Cell Metab, 2008, 1: 11-20.
6. Warburg O, Posener K, Negelein E. Ueber den Stoffwechsel der Tumoren. Biochemische Zeitschrift, 1924, 152: 319-344.
7. Mankoff D A, Eary J F, Link J M, et al. Tumor-specific positron emission tomography imaging in patients: [18F] fluorodeoxyglucose and beyond. Clin Cancer Res, 2007, 13: 3460-3469.
8. Dang C V. MyC, microRNAs and glutamine addiction in cancers. Cell Cycle, 2009, 8: 3243-3256.
9. Mashima T, Seimiya H, Tsuruo T. De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. British Journal of Cancer, 2009, 100: 1369-1372.
10. Racker E. History of the Pasteur effect and its pathobiology. Mol Cell Biochem, 1974, 5: 17-23.
11. Denkert C, Budczies J, Weichert W, et al. Metabolite profiling of human colon carcinoma deregulation of TCA cycle and amino acid turnover. Mol Cancer, 2008, 7: 72-88.
12. Hirayama A, Kami K, Sugimoto M, et al. Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res, 2009, 69: 4918-4925.
13. Rocha C M, Barros A S, Gil A M, et al. Metabolic profiling of human lung cancer tissue by 1H high resolution magic angle spinning (HRMAS) NMR spectroscopy. J Proteome Res, 2010, 9: 319-332.
14. Denkert C, Budczies J, Kind T, et al. Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. Cancer Res, 2006, 66: 10795-10804.
15. Boren J, Cascante M, Marin S, et al. Gleevec (STI571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells. J Biol Chem, 2001, 276: 37747-37753.
16. Boros L G, Torday J S, Li S, et al. Transforming growth factor beta2 promotes glucose carbon incorporation into nucleic acid ribose through the nonoxidative pentose cycle in lung epithelial carcinoma cells. Cancer Res, 2000, 60: 1183-1185.
17. Gatenby R A, Gillies R J. Why do cancers have high aerobic glycolysis. Nat Rev Cancer, 2004, 4: 891-899.
18. DeBerardinis R J, Mancuso A, Daikhin E, et al. Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA, 2007, 104: 19345-19350.
19. Christofk H R, Vander Heiden M G, Harris M H, et al. TheM2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature, 2008, 452: 230-234.
20. Swietach P, Vaughan-Jones R D, Harris A L. Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev, 2007, 26: 299-310.
21. Fischer K, Hoffmann P, Voelkl S, et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood, 2007, 109: 3812-3819.
22. Sonveaux P, Végran F, Schroeder T, et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest, 2008, 118: 3930-3942.
23. Vander Heiden M G, Cantley L C, Thompson C B. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science, 2009, 324: 1029-1033.
24. Helmlinger G, Yuan F, Dellian M, et al. Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med, 1997, 3: 177-182.
25. Gottschalk S, Anderson N, Hainz C, et al. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABLPositive cells. Clin Cancer Res, 2004, 10: 6661-6668.
26. Giatromanolaki A, Koukourakis M I, Sivridis E, et al. Relation of hypoxia inducible factor 1α and 2α in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer, 2001, 85: 881-890.
27. Yun J, Rago C, Cheong I, et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science, 2009, 325: 1555-1559.
28. Shaw R J, Cantley L C. Ras, PI (3)K and mTOR signalling controls tumour cell growth. Nature, 2006, 441: 424-430.
29. Dang C V, Le A, Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res, 2009, 15: 6479-6483.
30. Zhao Y H, Zhou M, Liu H, et al. Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth. Oncogene, 2009, 28: 3689-3701.
31. Liu X, Wang X, Zhang J, et al. Warburg effect revisited: an epigenetic link between glycolysis and gastric carcinogenesis. Oncogene, 2010, 29: 442-450.
32. Warburg O. On the origin of cancer cells. Science, 1956, 123: 309-314.
33. Pedersen P L. Tumor mitochondria and the bioenergetics of cancer cells. Prog Exp Tumor Res, 1978, 22: 190-274.
34. Lopez-Rios F, Sanchez-Arago M, García-García E, et al. Loss of the mitochondrial bioenergetic capacity underlies the glucose avidity of carcinomas. Cancer Res, 2007, 67: 9013-9017.
35. Pouyssegur J, Dayan F, Mazure N M. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature, 2006, 441: 437-443.
36. Semenza G L. Hypoxia-inducible factor 1 (HIF-1) pathway. Sci STKE, 2007: cm8.
37. Harris A L. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer, 2002, 2: 38-47.
38. Taylor C T, Pouyssegur J. Oxygen, hypoxia, and stress. Ann New York Acad Sci, 2007, 1113: 87-94.
39. Liu R, Li Z, Bai S, et al. Mechanism of cancer cell adaptation to metabolic stress. Mol Cell Proteomics, 2008, 8: 70-85.
40. Denko N C. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer, 2008, 8: 705-713.
41. Gottlieb E, Tomlinson I P. Mitochondrial tumour suppressors: A genetic and biochemical update. Nat Rev Cancer, 2005, 5: 857-866.
42. Bárdos J I, Ashcroft M. Hypoxia-inducible factor-1 and oncogenic signalling. Bioessays, 2004, 26: 262-269.
43. Selak M A, Armour S M, MacKenzie E D, et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase. Cancer Cell, 2005, 7: 77-85.
44. Ratcliffe J. Fumarate Hydratase Defciency and Cancer: Activation of Hypoxia Signaling? Cancer Cell, 2007, 11: 303-305.
45. Papandreou I, Cairns R A, Fontana L, et al. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab, 2006, 3: 187-197.
46. Jung Y J, Isaacs J S, Lee S, et al. IL-1β mediated up-regulation of HIF-1α via an NFkB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J, 2003, 17: 2115-2117.
47. Feldser D, Agani F, Iyer N V, et al. Reciprocal positive regulation of hypoxia-inducible factor 1a and insulin-like growth factor 2. Cancer Res, 1999, 59: 3915-3918.
48. Spangenberg C, Lausch E U, Trost T M, et al. ERBB2-mediated transcriptional up-regulation of the A5B1 integrin fibronectin receptor promotes tumor cell survival under adverse conditions. Cancer Res, 2006, 66: 3715-3725.
49. Peng X H, Karna P, Cao Z, et al. Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1α signal pathways increases resistance to Apoptosis by up-regulating survivin gene expression. J Biol Chem, 2006, 281: 25903-25914.
50. Mottet D, Dumont V, Deccache Y, et al. Regulation of hypoxia-inducible factor-1α protein level during hypoxic conditions by the phosphatidylinositol 3-Kinase/Akt/Glycogen synthase kinase 3β pathway in HepG2 cells. J Biol Chem, 2003, 278: 31277-31285.
51. Isaacs J S, Jung Y J, Neckers L. Aryl hydrocarbon nuclear translocator (ARNT) promotes oxygen-independent stabilization of hypoxia-inducible factor-1α by modulating an Hsp90-dependent J Biol Chem, 2004, 279: 16128-16135.
52. Mabjeesh N J, Escuin D, LaVallee T M, et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell, 2003, 3: 363-375.
53. Welsh S J, Williams R R, Birmingham A, et al. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1α and vascular endothelial growth factor formation. Mol Cancer Ther, 2003, 2: 235-243.
54. Fath D M, Kong X G, Liang D M, et al. Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-α. J Biol Chem, 2006, 281: 13612-13619.
55. Chen C H, Pore N, Behrooz A, et al. Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J Biol Chem, 2001, 276: 9519-9525.
56. Maxwell P H, Dachs G U, Gleadle J M, et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA, 1997, 94: 8104-8109.
57. Kim J W, Gao P, Liu Y C, et al. HIF-1 and dysregulated c-Myc cooperatively induces VEGF and metabolic switches, HK2 and PDK1. Mol Cell Biol, 2007.
58. Tacchini L, Bianchi L, Bernelli-Zazzera A, et al. Transferrin receptor induction by hypoxia. HIF-1-mediated transcriptional activation and cell-specific post-transcriptional regulation. J Biol Chem, 1999, 274: 24142-24146.
59. Semenza G L and Wang G L. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol, 1992, 12: 5447-5454.
60. Fantin V R, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell, 2006, 9: 425-434.
61. Semenza G L. Tumor metabolism: cancer cells give and take lactate. J Clin Invest, 2008, 118: 3835-3837.
62. Patel M S and Korotchkina L G. Regulation of mammalian pyruvate dehydrogenase complex by phosphorylation: complexity of multiple phosphorylation sites and kinases. Exp Mol Med, 2001, 33: 191-197.
63. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell, 2008, 13: 472-482.
64. Ohgaki H. Genetic pathways to glioblastomas. Neuropathology, 2005. 25: 1-7.
65. Liang M C, Ma J, Chen L, et al. TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity. Oncogene, 2009, 29: 1588-1597.
66. Brugarolas J B, Vazquez F, Reddy A, et al. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell, 2003, 4: 147-158.
67. Pedrero J M, Carracedo D G, Pinto C M, et al. Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma. Int J Cancer, 2005, 114: 242-248.
68. Bellacosa A, Feo D D, Godwin A K, et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer, 1995, 64: 280-285.
69. Kurzrock R, Kantarjian H M, Druker B J, et al. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann Int Med, 2003, 138: 819-830.
70. Slamon D J, Godolphin W, Jones L A, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 1989, 244: 707-712.
71. Cappuzzo F, Hirsch F R, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst, 2005, 97: 643-655.
72. Schwartzenberg-Bar-Yoseph F, Armoni M, Karnieli E. The Tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res, 2004, 64: 2627-2633.
73. Bensaad K, Tsuruta A, Selak M A, et al. TIGAR, a p53-inducible regulator of glycolysis and Apoptosis. Cell, 2006, 126: 107-120.
74. Matoba S, Kang J G, Patino W D, et al. p53 regulates mitochondrial respiration. Science, 2006, 312: 1650-1653.
75. Parsons D W, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science, 2008, 321: 1807-1812.
76. Yan H, Parsons D W, Jin G, et al. IDH1 and IDH2 mutations in Gliomas. New Engl J Med, 2009, 360: 765-773.
77. Medes G, Thomas A, Weinhouse S. Metabolism of neoplastic tissue IV: a study of lipid synthesis in neoplastic tissue slices in vitro. Cancer Res, 1953, 13: 27-29.
78. Menendez J A, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer, 2007, 7: 763-777.
79. Hatzivassiliou G, Zhao F, Bauer D E, et al. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell, 2005, 8: 311-321.
80. Parlo R A, Coleman S. Enhanced rate of citrate export from cholesterol-rich hepatoma mitochondria. The truncated Krebs cycle and other metabolic ramifications of mitochondrial membrane cholesterol. J Biol Chem, 1984, 259: 9997-10003.
81. Chajès V, Moreau K, Moreau K, et al. Acetyl-CoA Carboxylase A Is Essential to Breast Cancer Cell Survival. Cancer Res, 2006, 66: 5287-5294.
82. Migita T, Narita T, Nomura K, et al. ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer. Cancer Res, 2008, 68: 8547-8554.
83. Kuhajda F P. Fatty Acid synthase and cancer: new application of an old pathway. Cancer Res, 2006, 66: 5977-5980.
84. McGarry J D, Brown N F. The mitochondrial carnitine palmitoyltransferase system from concept to molecular analysis. Eur J Biochem, 1997, 244: 1-14.
85. Kuhajda F P. Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition, 2000, 16: 202-208.
86. Deberardinis R J, Sayed N, Ditsworth D, et al. Brick by brick: metabolism and tumor cell growth. Curr Opin Gen Dev, 2008, 18: 54-61.
87. Fackler O T, Grosse R. Cell motility through plasma membrane blebbing. J Biol Chem, 2008, 181: 879-884.
88. Stylli S S, Kaye A H, Lock P. Invadopodia: at the cutting edge of tumour invasion. J Clin Neurosci, 2008, 15: 725-737.
89. Zunder E R, Knight Z A, Houseman B T, et al. Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alpha. Cancer Cell, 2008, 14: 180-192.
90. Ren J, Xiao Y J, Singh L S, et al. Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells. Cancer Res, 2006, 66: 3006-3014.
91. Fukuda H, Iritani N, Sugimoto T, et al. Transcriptional regulation of fatty acid synthase by insulin/glucose, polyunsaturated fatty acids and leptin in hepatocytes and adipocytes in normal and genetically obese rats. Eur J Biochem, 1999, 260: 505-511.
92. Swinnen J V, Heemers H, Deboel L, et al. Stimulation of tumorassociated fatty acid synthase expression by growth factor activation of the sterol regulatory element-binding protein pathway. Oncogene, 2000, 19: 5173-5181.
93. Oskouian B. Overexpression of fatty acid synthase in SKBR3 breast cancer cell line is mediated via a transcriptional mechanism. Cancer Lett, 2000, 149: 43-51.
94. Kumar-Sinha C, Ignatoski K W, Lippman M E, et al. Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis. Cancer Res, 2003, 63: 132-139.
95. Menendez J A, Santiago R, Inderjit M, et al. Overexpression and hyperactivity of breast cancer-associated fatty acid synthase (oncogenic antigen-519) is insensitive to normal arachidonic fatty acid-induced suppression in lipogenic tissues but it is selectively inhibited by tumoricidal alpha-linolenic and gamma-linolenic fatty acids: a novel mechanism by which dietary fat can alter mammary tumorigenesis. Int J Cancer, 2004, 24: 1369-1383.
96. van de Sande T, De Schrijver E, Heyns W, et al. Role of the phosphatidylinositol 3′-kinase/PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells. Cancer Res, 2002, 62: 642-646.
97. Porstmannm T, Griffiths B, Chung Y L, et al. PKB/AKT induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP. Oncogene, 2005, 24: 6465-6481.
98. Yang Y A, Han W F, Morin P J, et al. Activation of fatty acid synthesis during neoplastic transformation: role of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Exp Cell Res, 2002, 279: 80-90.
99. Guo D, Prins R M, Dang J, et al. EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci Signal, 2009, 2: ra82.
100. Chalbos D, Chambon M, Ailhaud G, et al. Fatty acid synthetase and its mRNA are induced by progestins in breast cancer cells. J Biol Chem, 1987, 262: 9923-9926.
101. Chambon M, Rochefort H, Vial H J, et al. Progestins and androgens stimulate lipid accumulation in T47D breast cancer cells via their own receptors. J Steroid Biochem, 1989, 33: 915-922.
102. Swinnen J V, Esquenet M, Goossens K, et al. Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCa. Cancer Res, 1997, 57: 1086-1090.
103. Ettinger S L, Sobel R, Whitmore T G, et al. Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Res, 2004, 64: 2212-2221.
104. Krycer J R, Sharpe L J, Luu W, et al. The Akt-SREBP nexus: cell signaling meets lipid metabolism. Trends Endocrin Met, 2010.
105. Eberle D, Hegarty B, Bossard P, et al. SREBP transcription factors: master regulators of lipid homeostasis. Biochimie, 2004, 86: 839-848.
106. Ettinger S L, Sobel R, Whitmore T G, et al. Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Res, 2004, 64: 2212-2221.
107. Yang Y A, Morin P J, Han W F, et al. Regulation of fatty acid synthase expression in breast cancer by sterol regulatory elements binding protein-1c. Exp Cell Res, 2003, 282: 132-137.
108. Menendez J A, Decker J, Lupu R. In support of fatty acid synthase (FAS) as a metabolic oncogene: extracellular acidosis acts in an epigenetic fashion activating FAS gene expression in cancer cells. J Cell Biochem, 2005, 94: 1-4.
109. Porstmann T, Santos C R, Griffiths B, et al. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Met, 2008, 8: 224-236.
110. Bengoechea-Alonso M T, Ericsson J. A phosphorylation cascade controls the degradation of active SREBP1. J Biol Chem, 2009, 284: 5885-5895.
111. Bengoechea-Alonso M T, Ericsson J. SREBP in signal transduction: cholesterol metabolism and beyond. Curr Opin Cell Biol, 2007, 19: 215-222.
112. Heemers H, Maes B, Foufelle F, et al. Androgens stimulate lipogenic gene expression in prostate cancer cells by activation of the sterol regulatory element-binding protein cleavage activating protein/sterol regulatory element-binding protein pathway. Mol Endocrin, 2001, 15: 1817-1828.
113. Wells W A, Schwartz G N, Morganelli P M, et al. Expression of "Spot 14" (THRSP) predicts disease free survival in invasive breast cancer: immunohistochemical analysis of a new molecular marker. Breast Cancer Res Treat, 2006, 98: 231-240.
114. Long Y C, Zierath J R. AMP-activated protein kinase signaling in metabolic regulation. J Clin Invest, 2006, 116: 1776-1783.
115. Shackelford D B, Shaw R J. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer, 2009, 9: 563-575.
116. Graner E, Tang D, Rossi S, et al. The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer. Cancer Cell, 2004, 5: 253-261.
117. Yoon S, Li M Y, Park S W, et al. Up-regulation of acetyl-CoA carboxylase alpha and fatty acid synthase by human epidermal growth factor receptor 2 at the translational level in breast cancer cells. J Biol Chem, 2007, 282: 26122-26131.
118. Shah U S, Dhir R, Gollin S M, et al. Fatty acid synthase gene overexpression and copy number gain in prostate adenocarcinoma. Hum Pathol, 2006, 37: 401-409.
119. Nomura D K, Long J Z, Niessen S, et al. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell, 2010, 140: 49-61.
120. Eagle H. The specific amino acid requirements of a human carcinoma cell (Stain HeLa) in tissue culture. J Exp Med, 1955, 102: 37-48.
121. DeBerardinis R J, Cheng T. Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene, 2010, 29: 313-324.
122. DeBerardinis R J, Lum J J, Hatzivassiliou G, et al. The Biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Met, 2008, 1: 11-20.
123. Wise D R, DeBerardinis R J, Mancuso A, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci USA, 2008, 105: 18782-18787.
124. Turner A, McGivan J D. Glutaminase isoform expression in cell lines derived from human colorectal adenomas and carcinomas. Biochem J, 2003, 370: 403-408.
125. Perez-Gomez C, Campos-Sandoval J A, Alonso F J, et al. Co-expression of glutaminase K and L isoenzymes in human tumour cells. Biochem J, 2005, 386: 535-542.
126. Aledo J C, Segura J A, Medina M A, et al. Phosphate-activated glutaminase expression during tumor development. FEBS Lett, 1994, 341: 39-42.
127. Lobo C, Ruiz-Bellido M A, Aledo J C, et al. Inhibition of glutaminase expression by antisense mRNA decreases growth and tumourigenicity of tumour cells. Biochem J, 2000, 348(Pt2): 257-261.
128. Portais J C, Voisin P, Merle M, et al. Glucose and glutamine metabolism in C6 glioma cells studied by carbon 13 NMR. Biochimie, 1996, 78: 155-164.
129. Yuneva M, Zamboni N, Oefner P, et al. Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. J Cell Biol, 2007, 178: 93-105.
130. DeBerardinis R J, Mancuso A, Daikhin E, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA, 2007, 104: 19345-19350.
131. Gao P, Tchernyshyov I, Chang T C, et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature, 2009, 458: 762-766.
132. Yuneva M, Zamboni N, Oefner P, et al. Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. J Cell Biol, 2007, 178: 93-105.
133. Dang C V. Rethinking the Warburg effect with Myc micromanaging Glutamine metabolism. Cancer Res, 2010, 70: 859-862.
134. Yang C, Sudderth J, Dang T, et al. Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. Cancer Res, 2009, 69: 7986-7993.
135. Kaadige M R, Looper R E, Kamalanaadhan S, et al. Glutamine-dependent anapleurosis dictates glucose uptake and cell growth by regulating MondoA transcriptional activity. Proc Natl Acad Sci USA, 2009, 106: 14878-14883.
136. Kelloff G J, Johnson B, Johnson B, et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res, 2005, 11: 2785-2808.
137. Vansteenkiste J F. PET scan in the staging of non-small cell lung cancer. Lung Cancer, 2003, 42(Suppl 1): S27-37.
138. Weber W A, Petersen V, Schmidt B, et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol, 2003, 21: 2651-2657.
139. Eubank W. Current and future uses of PET in breast cancer imaging. Semin Nucl Med, 2004, 34: 224-240.
140. Carroll P R, Coakley F V, Kurhanewicz J. Magnetic Resonance Imaging and Spectroscopy of Prostate. Cancer Rev Urol, 2006, 8(Suppl 1): S4-10.
141. Gao P, Zhang H, Dinavahi R, et al. HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell, 2007, 12: 230-238.
142. Ihrlund L S, Hernlund E, Khan O, et al. 3-Bromopyruvate as inhibitor of tumour cell energy metabolism and chemopotentiator of platinum drugs. Mol Oncol, 2008, 2: 94-101.
143. + channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell, 2007, 11: 37-51.
144. Zhou W, Han W F, Landree L E, et al. Fatty acid synthase inhibition activates AMP-activated protein kinase in SKOV3 human ovarian cancer cells. Cancer Res, 2007, 67: 2964-2971.
145. Simons A L, Ahmad I M, Mattson D M, et al. 2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. Cancer Res, 2007, 67: 3364-3370.
146. Stetak A, Veress R, Ovadi J, et al. Nuclear translocation of the tumor marker pyruvate kinase M2 induces programmed cell death. Cancer Res, 2007, 67: 1602-1608.
147. Beckers A, Organe S, Timmermans L, et al. Chemical inhibition of acetyl-CoA carboxylase induces growth arrest and cytotoxicity selectively in cancer cells. Cancer Res, 2007, 67: 8180-8187.
148. Glunde K, Jacobs M A, Bhujwalla Z M, et al. Choline metabolism in cancer: implications for diagnosis and therapy. Expert Rev Mol Diagno, 2006, 6: 821-829.
149. Fuchs B C, Bode B P. Amino acid transporters ASCT2 and LAT1 in cancer: Partners in crime? Semin Cancer Biol, 2005, 15: 254-266.
150. Kong D, Park E J, Stephen A G, et al. Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res, 2005, 65: 9047-9055.
151. MacKenzie E D, Selak M A, Tennant D A, et al. Cell-permeating alpha-ketoglutarate derivatives alleviate pseudohypoxia in succinate dehydrogenase-deficient cells. Mol Cell Biol, 2007, 27: 3282-3289.
152. Brizel D M, Esclamado R. Concurrent chemoradiotherapy for locally advanced, nonmetastatic, squamous carcinoma of the head and neck: consensus, controversy, and conundrum. J Clin Oncol, 2006, 24: 2612-2617.
153. Thiry A, Dogne J M, Masereel B, et al. Targeting tumor-associated carbonic anhydrase IX in cancer therapy. Trends Pharm Sci, 2006, 27: 566-573.
154. Chi S L, Wahl M L, Mowery Y M, et al. Angiostatin-like activity of a monoclonal antibody to the catalytic subunit of F1F0 ATP synthase. Cancer Res, 2007, 67: 4716-4724.
155. Evans J M M, Ogston S A, Emslie-Smith A, et al. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia, 2006, 49: 930-936.
156. Graff J R, Konicek B W, Vincent T M, et al. Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest, 2007, 117: 2638-2648.
157. Cheran S K, Nielson N D, Patz E F. False-negative findings for primary lung tumors on fdg positron emission tomography: staging and prognostic implications. Am J Roentgenol, 2004, 182: 1129-1132.